XML 77 R40.htm IDEA: XBRL DOCUMENT v3.3.1.900
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2015
Income Tax Disclosure [Abstract]  
Components of Income Tax Expense

The components of income tax expense are as follows:

 

 

 

Years Ended December 31,

 

 

 

2015

 

 

2014

 

Current:

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

State

 

 

10,189

 

 

 

 

Total current income tax expense

 

$

10,189

 

 

$

 

 

 

 

 

 

 

 

 

 

Deferred:

 

 

 

 

 

 

 

 

Federal

 

$

 

 

$

 

State

 

 

 

 

 

 

Total deferred income tax expense

 

$

 

 

$

 

Total income tax expense

 

$

10,189

 

 

$

 

 

Schedule of Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes

 

The Company’s actual income tax expense for the years 2015 and 2014 differ from the expected amount computed by applying the statutory federal income tax rate of 34% to loss before income taxes as follows:

 

 

 

Years Ended December 31,

 

 

 

2015

 

 

2014

 

Computed tax (benefit) at 34%

 

$

(7,271,785

)

 

$

(4,745,859

)

State taxes, net of federal benefit

 

 

(918,079

)

 

 

(233,632

)

Stock-based compensation

 

 

102,699

 

 

 

59,119

 

Expiring state net operating loss ("NOL") carryforwards

 

 

(20,086

)

 

 

131,342

 

Return to provision

 

 

(27,934

)

 

 

(4,269

)

Other

 

 

44,679

 

 

 

37,969

 

Research and development tax credit - state

 

 

(300,213

)

 

 

(20,720

)

Research and development tax credit - federal

 

 

(342,681

)

 

 

(11,224

)

Change in valuation reserve

 

 

8,743,589

 

 

 

4,787,274

 

 

 

$

10,189

 

 

$

 

 

Schedule of Deferred Tax Assets and Liabilities

 

Deferred tax assets and liabilities comprise the following:

 

 

 

Years Ended December 31,

 

 

 

2015

 

 

2014

 

Deferred tax assets:

 

 

 

 

 

 

 

 

Net operating loss carryforwards

 

$

28,795,562

 

 

$

20,977,060

 

Research and development credits

 

 

1,435,314

 

 

 

796,328

 

Deferred revenue

 

 

17,396

 

 

 

15,166

 

Inventory reserve

 

 

104,182

 

 

 

19,953

 

Fixed assets and intangibles

 

 

50,128

 

 

 

53,822

 

Change in fair value of warrant liability

 

 

111,993

 

 

 

3,541

 

Accrued NuvoGen liability

 

 

3,282,756

 

 

 

3,190,603

 

Capitalized research and development

 

 

27,583

 

 

 

55,354

 

Other

 

 

115,792

 

 

 

85,290

 

 

 

 

33,940,706

 

 

 

25,197,117

 

Valuation allowance

 

 

(33,940,706

)

 

 

(25,197,117

)

Deferred tax asset, net

 

$

 

 

$

 

 

Summary of Federal Net Operating Loss Carryforwards

The Company’s federal NOL carryforwards have the following expiration dates:

 

 

Year of Expiration

 

Carryforwards

 

Federal NOL carryforwards

 

 

 

 

 

 

 

 

2021

 

$

211,806

 

 

 

2023

 

 

1,635,651

 

 

 

2024

 

 

1,217,290

 

 

 

2025

 

 

1,409,498

 

 

 

2026

 

 

1,175,594

 

 

 

2027

 

 

1,676,458

 

 

 

2028

 

 

3,037,785

 

 

 

2029

 

 

3,753,314

 

 

 

2030

 

 

623,235

 

 

 

2031

 

 

5,435,312

 

 

 

2032

 

 

10,913,787

 

 

 

2033

 

 

12,095,966

 

 

 

2034

 

 

14,190,409

 

 

 

2035

 

 

21,120,642

 

 

 

 

 

$

78,496,747